Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV-101
- Development stage
- Phase 1
- Lead developer
- Syncromune
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
**SV-101** is an investigational multi-target immunotherapy drug developed by Syncromune for use in the SYNC-T in situ cancer-immunotherapy approach. In Phase 1 studies, controlled partial tumor cryolysis is followed by intratumoral administration of SV-101, with the aim of releasing patient-specific tumor antigens and locally delivering multiple immunomodulatory agents to stimulate antitumor T-cell responses while counteracting tumor immune evasion. SV-101 has been studied in patients with advanced or metastatic solid tumors, including metastatic breast cancer and metastatic non-small cell lung cancer.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD28 (Cluster of Differentiation 28)TLR9 (Toll-like receptor 9)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on SV-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV-101.